GRTS Gritstone Oncology

Gritstone to Participate in Upcoming Investor Conferences

Gritstone to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Gritstone management will participate in the following upcoming investor conferences.

5th Annual Evercore ISI HealthCONx Conference

Fireside Chat Date and Time: Tuesday, November 29, 2022 at 10:30am EST

Presenter: Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer

Location: Virtual

Webcast:

34th Annual Piper Sandler Healthcare Conference

Fireside Chat Date and Time: Thursday, December 1, 2022 at 2:30pm EST

Presenter: Celia Economides, Chief Financial Officer and Matthew J. Hawryluk, Chief Business Officer

Location: New York, NY

Webcast:

The presentations can be viewed live via the Investors & Media section of Gritstone’s website at . An archived replay will be accessible for 30 days following the event.

About Gritstone bio

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease.

Gritstone Contacts

Investors:

George E. MacDougall

Director, Investor Relations & Corporate Communications

Gritstone bio

Media:

Dan Budwick

1AB

(973) 271-6085



EN
17/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Gritstone Oncology

 PRESS RELEASE

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for...

Gritstone bio Announces Strengthening of Maturing Phase 2 PFS Data for GRANITE Study and Provides Business Update -- 27% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA subgroup (HR=0.50 [90% CI, 0.20-1.28]) -- -- Progressing through court-administered financial restructuring process with continued interest from multiple parties  EMERYVILLE, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (O...

 PRESS RELEASE

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualize...

Gritstone bio Announces Interim Phase 2 Data for GRANITE Individualized Neoantigen Targeting Immunotherapy in Frontline Metastatic Microsatellite Stable Colorectal Cancer --Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly --21% relative risk reduction of progression or death with GRANITE vs. control in all treated population (HR=0.79 [95% CI, 0.42-1.50])-- -- 38% relative risk reduction of progression or death with GRANITE vs. control in low ctDNA s...

 PRESS RELEASE

Gritstone bio Reports Second Quarter 2024 Financial Results and Provid...

Gritstone bio Reports Second Quarter 2024 Financial Results and Provides Corporate Updates -- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 -- -- Recent KOL event and patient advocacy engagements underscore the unmet need for new treatment options in metastatic colorectal cancer -- -- Presentations at AACR 2024 and ESCMID Global 2024 demonstrate the broad...

 PRESS RELEASE

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Pote...

Gritstone bio to Host Virtual KOL Event to Discuss Unmet Need and Potential Role of Its Personalized Cancer Vaccine, GRANITE, in Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) -- Event will feature Dr. Randolph Hecht (Professor, UCLA GI Oncology Program) and Howard Brown (CRC Survivor, Patient and Advocate) -- EMERYVILLE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced it will host a virtual key opinion leader (KOL) event on Friday, Aug...

 PRESS RELEASE

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 56...

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) EMERYVILLE, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the Compensation Committee of the company’s Board of Directors granted one employee nonqualified stock options to purchase an aggregate of 39,000 shares of its common stock with an exercise price of $0.57, which is equal to the closing price of Gritstone’s common stock on July 3, 2024, the date of the grant. T...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch